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A B S T R A C T
Introduction. Phosphodiesterase type 5 inhibitors (PDE5) are currently the ﬁrst line treatment for erectile dysfunc-
tion (ED). However, previous research shows that PDE5 treatments have high discontinuation rates. Understanding
the reasons for discontinuing PDE5 will be necessary to optimize the response to treatment.
Aim. The main goals were: (i) to analyze discontinuation rate of PDE5; (ii) to identify the discontinuation
predictors; and (iii) to study the reasons for discontinuation using a qualitative methodology.
Main Outcome Measures. The PDE5 discontinuation rates, predictors, and reasons for discontinuation treatment.
Methods. A total of 327 men with clinical diagnosis for ED who had been treated with PDE5 were successfully
interviewed by telephone, after giving their informed consent by snail mail. Telephone interviews, concerning their
ongoing treatment, were carried out using a standardized questionnaire form with quantitative and qualitative items.
Participation rate was 71.8%.
Results. Of the total sample, 160 men (48.9%) had discontinued PDE5 treatment. The discontinuation rate was
higher among men with diabetes (73%) and in iatrogenic group (65%), and lower in venogenic etiology (38.7%). We
differentiated three groups of men who discontinued treatment (i) during the ﬁrst 3 months (55.1%); (ii) between 4
and 12 months (26.9%); and (iii) after a period of 12 months (18%). Qualitative analyses revealed diverse reasons for
discontinuation: non-effectiveness of PDE5 (36.8%), psychological factors (e.g., anxiety, negative emotions, fears,
concerns, dysfunctional beliefs) (17.5%), erection recovery (14.4%), and concerns about the cardiovascular safety of
PDE5 (8.7%) were the most common. Older men and men whose partners were involved in the treatment, were less
likely to discontinue treatment.
Conclusion. Half the subjects discontinued medication. Mostly, there was a combination of factors that led to
discontinuation: non-effectiveness and psychosocial factors appear to be the main reasons. Addressing those factors
will allow following up with appropriate focus on relevant topics in order to improve compliance. Carvalheira AA,
Pereira NM, Maroco J, and Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: A study
on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361–2369.
Key Words. Erectile Dysfunction; PDE5; Dropout; Vardenalﬁl; Sildenaﬁl; Tadalaﬁl
Introduction
The emergence of the ﬁrst inhibitor of phos-phodiesterase type 5 (PDE5) (sildenaﬁl)
revolutionized the therapeutic intervention on
men’s sexual health. There is clear evidence that
phosphodiesterase inhibitors are efﬁcacious in the
treatment of the broad population of men with
erectile dysfunction (ED) (see [1] for a revision).
However, despite the good outcomes of PDE5
[2–4], high rates of treatment discontinuation were
present in several studies, ranging from 14% to
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57% [5–8]. Higher PDE5 discontinuation rates
were found in other studies, reaching 80.4% [9,10].
As recently suggested [11], this phenomenon led to
a central issue in PDE5 treatment: if erectile func-
tion is so important for well-being, self-esteem, and
relationships, and there is an easy and effective way
to treat ED, why do men discontinue treatment?
The answer to this question can only be found in
the complex relationship between efﬁcacy, treat-
ment satisfaction, adverse effects, safety concerns,
cost, and multiple psychosocial factors [12].
Moreover, data available suggest that the
reasons for treatment discontinuation can be
divided into “absolute” and “relative” [11]. The
absolute reasons refer to medical problems, lack of
efﬁcacy, and severe side effects. However, these are
not the reasons for discontinuation for some
patients, which may be due to more “obscure”
reasons: effect less than anticipated, lack of spon-
taneity, decreasing libido, disharmony in partner
relationships, increasing age, and a variety of
comorbidities [6–8,11,13].
Several studies reported treatment-related
reasons that may be responsible for discontinuation:
lack of efﬁcacy, side effects, fear of side effects,
unwillingness to accept drug-dependent erection,
inconvenience in obtaining sildenaﬁl, and change to
another ED treatment [5,10–12,14–18]. Further-
more, some studies have reported yet further reasons
for treatment discontinuation, namely: lack of
opportunity for sexual intercourse, partners’ or
patients’ emotional willingness for resuming sexual
activity, unacceptability of planned sexual activity,
and the quality of the relationship [5–7,12,14,15,19].
There appears to be a large number of patients
who never start, or discontinue, the treatment due
to its ﬁnancial cost [8,14]. However, several studies
contradict this statement, showing that the
dropout rate due to the cost is low [6,7]. According
to ﬁndings from the Cologne study, in a sample of
8,000 men, almost half were willing to pay 25
Euros per month for ED treatment, and 8% were
willing to pay any amount [20].
As has been suggested, the only positive reason
for discontinuing PDE5 is when the patient is
“cured” of his ED, being that erectile function
recovery is cited as one of the reasons for PDE5
discontinuation [7,8,10,11,14,21].
Determining the reasons for discontinuation,
and compliance with PDE5 treatments, appears to
be a fundamental issue in order to optimize the
response to treatment, and to develop strategies to
reduce the dropout rate (or to improve compli-
ance). Additionally, speciﬁc factors should be
addressed when choosing the best PDE5 for the
individual patient, creating an individualized treat-
ment plan [22,23]. A better understanding of
diversity of reasons for discontinuation at different
follow-up moments will allow an appropriate focus
on common issues and relevant factors. We believe
the best way to achieve this information and
knowledge is through a qualitative study.
Qualitative methods are based on different epis-
temological assumptions from those in quantita-
tive approaches, and can be especially useful for
studying the individuals’ experiential dimension
[24]. The phenomenological approach is a quali-
tative method that aims at probing participants to
relay individual meanings or lived experiences of a
given phenomenon [25]. We believe that this
approach is specially suited for the study of men’s
experience of taking and abandoning the PDE5.
Aims
The aims of this study were: (i) to analyze the
PDE5 discontinuation rate; (ii) to identify the pre-
dictors of discontinuation; and (iii) to study the
reasons for PDE5 discontinuation. Our main goal
was to make a qualitative analysis to achieve a
thorough understanding of the men’s reasons for
discontinuing treatment. In the case of an experi-
ential dimension, which is personal, and may be
multifactorial, we believe that a qualitative method
is most suited. Nevertheless, in addition to a
content analysis, we made a quantitative analysis to
study the reasons for PDE5 discontinuation.
Methods
Participants
Demographic Variables
A total of 327 men, with clinical diagnosis for ED
and PDE5 prescription for longer than 6 months,
were successfully interviewed. The participation
rate was 71.8%. The average age of participants
was 56.30 (standard deviation 11.44, range 25–81).
Most were in a committed relationship (87.2%).
Data on educational level, marital status, and reli-
gion are presented in Table 1.
Health-Related Variables
A percentage of 22.9 were active smokers.
Instrument
A comprehensive, detailed questionnaire was
developed and piloted for this study, based on the
literature review and on the researcher’s clinical
experience.
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Our questionnaire is composed of 45 items, and
contemplated quantitative and qualitative variables
(incorporating sociodemographic, clinical, and
dropout-related items). Sociodemographic infor-
mation included age, educational level, religion,
sexual orientation, and marital and relationship
status. The health-related items included health
problems, comorbidities, ongoing medication,
smoking habits, substance abuse, and genital and
urinary surgeries.
Other quantitative variables included: partner
involvement in the patient’s treatment, partner’s
sexual activity, frequency and duration of PDE5
use, expectations regarding the PDE5, other treat-
ment options sought by men, frequency of
appointments, and satisfaction with their doctor.
Also, men were asked to rate the importance of 11
reasons for discontinuing PDE5, on a ﬁve-point
Likert scale (1—reason not at all important to discon-
tinue treatment to 5—reason completely important to
discontinue treatment).
If PDE5 was prescribed by the doctor and the
patient did not initiate treatment, an open-ended
question was made to assess the reasons that led
the patient to not initiate treatment.
The questionnaire also contemplated two open-
ended questions: (i) How did you take the inhibitor?;
and (ii) What reasons led you to stop medication?
Procedure
From the base cohort, we identiﬁed all patients
who had been diagnosed with ED and received
PDE5 prescription for longer than 6 months in an
andrological outpatient’s clinic, where the authors
worked. The patients eligible for this study were
men with clinical diagnosis of ED and with history
of PDE5 use or prescription. Exclusion criteria
were: taking antidepressant, history of alcohol
and substance abuse, hypogonadism, Peyronie’s
disease, and the presence of a severe psychopatho-
logical disorder. All the subjects did an intracav-
ernous alprostadil injection test, associated with
penile rigidometry (Rigiscan test) and a penile
Doppler ultrasound. When a veno-occlusive
dysfunction was suspected, a pharmacocavernos-
ometry was systematically performed. The classi-
ﬁcation of etiologies was made in six categories,
based on rigidometry, penile Doppler ultrasound,
and medical history: (i) arteriogenic (arterial insuf-
ﬁciency): shows an insufﬁcient rigidometry
response and penile Doppler ultrasound conﬁrms
a cavernosal arterial insufﬁciency; (ii) venogenic
(veno-occlusive dysfunction): medical history
reveals an history of unstable and/or short-lasting
erections, the rigidometry shows an oscillatory or
null response, and penile Doppler ultrasound does
not show arterial insufﬁciency; (iii) neurogenic:
cases of neurologic pathology (e.g., cerebral vas-
cular accident, spinal cord injury); (iv) diabetes:
included were men with an history of diabetes for
more than 20 years, and rigidometry conﬁrms
the diagnosis of organicity; (v) iatrogenic: based
on two criteria—medical history of radical
prostatectomy/brachytherapy/radiation therapy
for prostate cancer (iatrogenic medication-
induced etiology was not included) and rigidom-
etry conﬁrms the diagnosis of organicity; and (vi)
psychogenic: medical history suggests psychologi-
cal cause and rigidometry and penile Doppler
ultrasound did not suggest organicity.
The patients were contacted by telephone for
the study’s presentation and then received the
informed consent by regular mail at the discharge
address; at this point, full written information
about the project and its aims was provided. Sub-
jects were contacted for second time after 1 week.
Once conﬁrmation had been received from the
potential participants, a telephone interview was
scheduled. Interviews took between 30 and 50
minutes. No remuneration was provided. We
believed that telephone interviews are an adequate
method to collect data on such a private topic
Table 1 Participants’ characteristics
%
Educational level
<Ninth grade 9.2
Ninth grade 20.4
High school 28.3
Degree 34.9
Masters degree 3.6
PhD 3.6
Religion
Catholic (observant) 52.6
Catholic (practicing) 22.3
Other religion (observant) 0.6
Other religion (practicing) 2.4
No religion 22.0
Marital status
Married 65.4
Divorced/separated 18.3
Single 10.4
Common law 3.1
Widowed 2.8
Relationship status
In a committed relationship 87.2
Occasional partner 5.2
Without sexual partner 5.2
Not committed but with regular sexual partner 2.4
Sexual orientation
Heterosexual 98.2
Homosexual 1.8
Mean age 56.3 (SD 11.44, range 25–81)
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allowing for greater self-disclosure than face-to-
face interviews. Moreover, this method allowed
the inclusion of men from different and distant
regions.
Interviews were conducted by both the main
researcher and a trained research assistant. They
were carried out using the standardized question-
naire form in a Google Docs online research data-
base. A username and password were established to
ensure database security. Complete qualitative and
quantitative data from the interviews were intro-
duced directly through the live form and stored in
the database.
Pilot testing was carried out to test the proce-
dure, the database system, and the questionnaire in
order to be clear and understandable and to
provide comprehensive response choices. A
number of errors were identiﬁed and corrected
during pilot testing.
This study received ethical approval from the
Ethics Committee of the University Institute of
Applied Psychology and from the Ethics Commit-
tee of Lusófona University.
Statistical Analysis
All statistical analyses were performed with SPSS
(v. 19.0, SPSS Inc., Chicago, IL, USA). A logistic
regression was conducted to examine the predic-
tors of discontinuation of PDE5 in this sample.
We tested the association between the etiology of
ED and discontinuation rate with a chi-square test.
Signiﬁcant effects were assumed for P < 0.05.
Regarding open-ended questions, transcribed data
were organized into categories and a content
analysis was performed.
Results
Discontinuation Rate of PDE5
Of the total sample (N = 327) and during a
follow-up period of 3 years, 160 men (48.9%) dis-
continued PDE5 treatment, 148 men (45.3%)
were still using the inhibitor, and 19 (5.8%) did
not start the treatment although a doctor pre-
scribed it. The discontinuers mean age was
56.1 (min 27, max 79), 67.5% were married,
17.5% divorced/separated, 9.4% single, and 3.1%
widowers.
Among this group of discontinuers, 49.4% of
men used the PDE5 in every single intercourse.
Moreover, 35% of men had experienced one or
more adverse effects with PDE5. In addition,
37.5% had switched from one PDE5 to another,
and 50.6% had tried at least one other treatment
for ED, besides PDE5. Forty-six percent referred
that the treatment did not meet their expectations.
The main etiologies in the total sample were veno-
genic (24.2%) and arteriogenic (22.9%). The
highest dropout rates were observed in individuals
with diabetes (67.5%) and iatrogenic etiology
(59.7%) (Table 2).
The etiologic diagnosis was determined
through the evaluation of the clinical history,
blood tests, intracavernous Alprostadil injection
test associated with Rigiscan test, and penile
Doppler ultrasound. In some cases Pharmacocav-
ernosometry and pharmacocavernosography were
also used. The high percentage of venogenic eti-
ologies in the total sample (24.2%) and the rela-
tively low percentage of arteriogenic etiologies can
be explained by the fact that this is a specialized
center, where the most complex cases are referred
to.
Of these 160 men who discontinued treatment,
20.3% stated that their partner was little or sexu-
ally active, 42.1% reported that their partner was
active, and 37.6% responded “not too much or too
little.” Twenty-two percent of men who dropped
out stated that their partner did not know about
the treatment, 24% believe that the partner was
not involved in solving the problem, and 25.6% of
men were accompanied by their partners to the
consultation.
Predictors of Discontinuation
A logistic regression was conducted to assess
whether age, etiology, side effects, partner’s
involvement in the treatment, and partner’s level
of sexual activity could predict PDE5 discontinu-
ation. The overall model was found to be signiﬁ-
cant (c2 (16) = 46.912, P < 0.001). Older men were
less likely to discontinue treatment (odds ratio
[OR] = 0.956, P = 0.005). Men whose partner was
involved in the treatment were less likely to dis-
Table 2 Etiologies of ED in the total sample and
discontinuers
Etiology
Total sample,
N = 327 Dropout
With prescription
but did not start
treatment
n (%) n (%) n (%)
Venogenic 79 (24.2) 29 (36.7) 2 (2.5)
Arteriogenic 75 (22.9) 34 (45.9) 6 (8.0)
Iatrogenic 62 (19.0) 37 (59.7) 6 (9.6)
Psychogenic 50 (15.3) 23 (45.0) 1 (2.0)
Diabetic 40 (12.2) 28 (67.5) 4 (10.0)
Neurogenic 21 (6.4) 9 (42.9) 0 (0.0)
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continue the treatment, as compared with men
whose partner was not involved in the treatment
(OR = 0.345, P = 0.01). Men who reported side
effects were less likely to discontinue treatment
(OR = 0.396, P = 0.002). When compared with the
subjects with venogenic etiologies, there was a sig-
niﬁcant increase in the dropout in subjects with
arteriogenic (OR = 3.4, P = 0.01), diabetes
(OR = 6.9, P = 0.001), and iatrogenic (OR = 7.5,
P < 0.001). None of the other variables were sig-
niﬁcant predictors of dropout.
Characterization of the Three Dropout Groups
We analyzed the discontinuation rates in three
follow-up moments: (i) men who dropped out
during the ﬁrst 3 months (55.1%); (ii) men who
dropped out between 3 and 12 months (26.9%);
and (iii) men who dropped out after a period of 12
months (18%) (Table 3).
Correlation between Etiology and Discontinuation
We explored the correlation between the etiology
of ED and discontinuation rate. There was a sig-
niﬁcant correlation between these variables
c2 (6) = 18.125, P < 0.05. The dropout rate was
higher among men with diabetes (73%) and in
iatrogenic group (65%), and lower in the group of
venogenic etiology (38.7%). Men with venogenic
etiology were younger (mean age 48.2) than men
with diabetes (mean age 60.4) and iatrogenic eti-
ology (mean age 63.1).
Quantitative Analysis of Reasons for
Discontinuing PDE5
We used 11 items with a ﬁve-point Likert scale to
study the reasons for discontinuation. This quan-
titative analysis revealed that the main reasons for
PDE5 discontinuation were: the non-effectiveness
of PDE5 (38%), recovery of erections (22.3%),
and concerns about the cardiovascular safety of
PDE5 (15.7%). All reasons are presented in
Table 4.
Qualitative Analysis of Reasons for
Discontinuing PDE5
The subjects’ answers to the question, “What
reasons led you to stop taking the medication?” were
analyzed, and allowed the identiﬁcation of a
diverse set of reasons for discontinuation of the
drug, which are organized and presented in
Table 5. The main reason found was the lack of
efﬁcacy of PDE5, reported by 36% of subjects
(40% iatrogenic, 23% diabetes, 20% arterogenic,
6% venogenic, 6% psychogenic, and 5% neuro-
genic). Other reasons for the abandonment of the
drug were psychological factors including anxiety,
Table 3 Characterization of the 3 dropout groups
Group 1,
1–3 months
Group 2,
4–12 months
Group 3,
>12 months
n = 89 (%) n = 43, (%) n = 28, (%)
Mean age 57.45 53.05 57.86
Marital status
Married 64.8 70.5 72.4
Divorced/separated 21.6 9.1 17.2
Single 8.0 13.6 6.9
Cohabitation 3.4 2.3 0
Widowed 2.3 4.5 3.4
Relational status
In a committed relationship 87.5 90.9 75.9
Quantitative reasons for discontinuation
Cost 10.8 16.3 18.5
Would not take again even if paid by health assurance foundations 67 63.6 58.6
Concerns about cardiovascular safety of PDE5 19.1 9.3 14.8
Other treatments 4.8 18.6 11.1
Non-effectiveness 45.7 30.3 25.9
Fear of drug dependence 7.4 4.6 3.7
Lack of opportunity for sexual intercourse 5 14 25.9
Lack of spontaneity 8.8 7 11.1
Decreased sexual interest 3.8 7 7.4
Erection recovery 20.3 34.9 11.1
Secondary effects 11.4 12.2 14.8
Relational variables
Partner involved in treatment 62.7 50.0 48.1
Partner known about PDE5 treatment 80.7 65.9 75.9
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negative emotions, fears, concerns, and dysfunc-
tional believes, inherent to the use of PDE5
(17.5%), not taken into account in the therapeutic
intervention. Other reasons identiﬁed were the
recovery of erections (14.4%), side effects (10%),
relational or interpersonal factors that include
problems or conﬂicts in the relationship or
unavailable sexual partners (9.3%), and concerns
about cardiovascular safety of PDE5 (8.7%). The
high cost of medication was reported by only 6.6%
and mostly by men who dropped out after 1 year.
To clarify the importance of cost on the abandon-
ment of the drug, subjects were asked if they would
take the drug again if it was reimbursed. A per-
centage of 64.4 of men reported that they would
not return to taking the inhibitor even if it was
reimbursed, and 6.5% responded “I do not know.”
The other reasons for discontinuation are pre-
sented in Table 5. We also identiﬁed a small
group of “unclear reasons,” where individuals
who seem to hide the real reasons, or whose
speech is confusing and unclear, were included.
We also speciﬁed a group “When an erection is not
enough” (title of an article by Althof [12]) to iden-
tify two individuals who reported that the treat-
ment of ED is more than restoring the capacity to
have erections.
The main reasons given by the group that dis-
continued PDE5 in the ﬁrst 3 months (group 1)
were non-effectiveness, erection recovery, concern
about cardiovascular safety, and psychological
factors. Relational factors and side effects were
mentioned by signiﬁcantly more subjects who dis-
continued the treatment after 4 months (groups 2
and 3), and subjects who dropped out after 1 year
(group 3) also mentioned the high cost and
medical complications as reasons (see Table 5).
PatientsWho Did Not Start Treatment
A total of 19 patients (5.8%) never took PDE5,
although a doctor prescribed it. Their mean age
was 62 years (min 40, max 81), 89.5% were in a
committed relationship, 78.9% were married,
10.5% divorced/separated, 5.3% single, and 5.3%
widowed. Content analysis revealed the following
reasons for not initiating treatment with PDE5:
ﬁve men reported relational variables, mainly a not
sexually active partner, and ﬁve other men had
concerns about cardiovascular safety of PDE5.
Five men reported general concerns and resistance
to taking drugs, and one man complained about
the high cost of the pill. Three men reported
unclear reasons.
Discussion
Discontinuation Rate and Etiology
One goal of this study was to analyze the PDE5
discontinuation rate. In our sample of 327 men
with ED and PDE5 prescription for longer than 6
months, the discontinuation rate was 48.9%
during a follow-up period of 3 years. This ﬁnding
is supported by previous research [5–8,13,19]. Half
of the discontinuers used the inhibitor with every
intercourse, 35% referred to have experienced
some adverse effects, and 50.6% had already tried
other treatments for ED. The discontinuation rate
was higher among men with diabetes (73%) and in
iatrogenic group (65%), which can be explained by
the lower efﬁcacy of inhibitors on these etiologies.
The discontinuation rate was lower in the group of
venogenic etiology (38.7%), which can be
explained by the higher efﬁcacy of inhibitors in
this etiology and by the lower age of subjects.
Quantitative Analysis of Reasons for
Discontinuing PDE5
The majority of treatment discontinuations
occurred during the ﬁrst 3 months (55.1%).
According to the quantitative analysis, main
reasons to discontinue treatment during this
period were non-effectiveness, erection recovery,
and concerns about cardiovascular safety of the
inhibitor. In the period between 4 and 12 months,
the major reasons were non-effectiveness, erection
recovery, and other treatment options. Among
men who discontinued treatments after a period of
12 months, the main motives were non-
effectiveness, cost, and lack of opportunity for
sexual intercourse.
The high cost of the inhibitor is considered to
be one important motive evoked by patients to
Table 4 Quantitative data of reasons for discontinuation
of PDE5 (n = 160)
Reasons for discontinuation (quantitative data) %*
Non-effectiveness 38.0
Erection recovery 22.3
Concerns about cardiovascular safety of PDE5 15.7
Cost 13.7
Secondary effects 12.3
Lack of sexual opportunity 11.5
Other treatments 9.3
Lack of spontaneity 8.7
Fear of drug dependence 6.0
Decreased sexual interest 5.4
Constrain/embarrassment in obtaining the drug 2.7
*“To what extent have the following reasons contributed for you to have
stopped taking the pill?” Five-point Likert scale (nothing, little, not too much nor
too little, somewhat, a lot). This percentage is the sum of the categories
(somewhat and a lot).
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abandon treatment in some studies [8,10,14].
However, the present study does not conﬁrm it, as
showed by other studies [6,7,20]. Our ﬁndings
revealed that “high cost” was referenced by only
13.7% of the total sample of men who discontin-
ued treatment (N = 160). One possible explana-
tion for this result is the high economic level of the
participants, although the only indicator we have is
the 42% of subjects with high educational level.
However, only 28.5% of men who discontinued
treatment referred that they would return if paid
by health insurance (65% of men would not).
The non-effectiveness was the main reason in
the three groups. The meaning of this lack of
efﬁcacy is explained, in most subjects, by the ED
etiology (mainly iatrogenic and diabetes) and
comorbidities. Regarding the predictors for treat-
ment discontinuation, a signiﬁcant model
emerged. Older men and men whose partner was
involved in the treatment were less likely to dis-
continue treatment. Although unexpected, side
effects did not predict discontinuation. On the
contrary, men who reported side effects were less
likely to discontinue treatment. This result is con-
sonant with the qualitative results: side effects
were not a major reason to discontinue treatment
(only 12.3% of the participants). Thus, the quan-
titative analysis (consisting of items in a Likert
scale) was neither sufﬁcient nor adequate for a
more accurate disclosure of the factors involved in
the abandonment of treatment. Furthermore,
these data also corroborate the need and the
importance of a qualitative methodology to
assess the experiential dimension of treatment
discontinuation.
Qualitative Analysis of the Meaning
of Discontinuation
The content analysis revealed 14 different reasons
to discontinue the PDE5 treatment: non-
effectiveness, erection recovery, concerns about car-
diovascular safety of PDE5I, dysfunctional believes
inherent to the use of the inhibitor, emotional vari-
ables that cause personal distress, general concerns
and fears, unwillingness to accept drug-dependent
erections, side effects, relationship factors, high
cost, medical comorbidities that emerged during
treatment, an occasional use to improve perfor-
mance, and unclear reasons. This qualitative analy-
sis also showed that the discontinuation is more
frequently motivated by a combination of factors
than by a singular reason. Non-effectiveness
(mainly in iatrogenic etiology) and psychosocial
factors (e.g., fears, anxiety, negative emotions, dys-
functional believes, masculinity issues) appear to be
the main reasons for discontinuation of the treat-
ment. This result empirically supports Althof’s pro-
posal of considering (i) patient variables such as
anxiety or unrealistic expectations; (ii) partner vari-
ables; and (iii) interpersonal sexual and nonsexual
variables, such as the quality of the couple’s rela-
tionship [12] in the treatment approach.
Moreover, qualitative analysis also corroborates
some quantitative results: cost (mentioned by only
6.2% of subjects) and side effects (referred by
10.6%), are not compelling reasons to abandon
treatment.
These ﬁndings enlighten the importance of
taking into account this diversity of reasons in the
moment of prescription and during the follow-up.
Conclusion
Results on qualitative analysis show the necessity
to address some topics at the moment of pre-
scription, namely to discuss treatment goals and
expectations, demystify certain beliefs and misper-
ceptions, discuss partner issues, and identify fears
and concerns about the drug. The adequacy of
education in the initial treatment period may
impact positively the compliance with PDE5 treat-
ment. Findings also revealed the necessity to
address psychological and relational variables
during follow-up: concerns and fears, as well as
dysfunctional beliefs inherent to the use of PDE5,
negative emotions, and relational/interpersonal
problems, such as the incapacity to resuming
sexual activity or erotic discrepancies.
There are limitations in this study that must be
considered. The research was developed with a
sample of men that went to a private clinic for ED,
which cannot be assumed to be representative of
all men suffering from ED (due to the economic
status and the clinic being very specialized).
Because of the private healthcare setting, the study
population is not totally representative of all social
and demographic variables. We also assume that
patients of higher socioeconomic status were over-
represented. Furthermore, a small number of men
were not able (or did not want) to specify the
reason for discontinue treatment, merely stating,
“It didn’t work,” or were not willing or able to
provide further explanations.
We believe that the strength of this study is the
analysis of men’s narratives on their reasons to
discontinue treatment, which revealed a combina-
tion of factors. To acknowledge those factors will
allow following up with appropriate focus on rel-
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evant topics in order to optimize the response to
treatment of ED with PDE5. A combined treat-
ment approach might be fundamental in some
cases.
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